Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: A review

Journal of Clinical Psychopharmacology

Volumn 18, Issue 1, 1998, Pages 38-49

  Solomon, David A ^a,b   Keitner, Gabor I ^a   Ryan, Christine E ^a   Miller, Ivan W ^a  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; FLUOXETINE; HALOPERIDOL; LIOTHYRONINE; LITHIUM; NEUROLEPTIC AGENT; THYRONINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

DRUG EFFICACY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CARBONATE; VALPROIC ACID;

EID: 0031974545     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199802000-00007     Document Type: Review

References (99)

1. Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Bruce ML, Florio LP. Affective disorders in five United States communities. Psychol Med 1988;18:141-53.
2. Burke KC, Burke JD Jr, Regier DA, Rae DS. Age at onset of selected mental disorders in five community populations. Arch Gen Psychiatry 1990;47:511-8.
3. Keller MB, Lavori PW, Coryell W, Endicott J, Mueller TI. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis 1993;181: 238-45.
4. Keller MB, Lavori PW, Kane JM, Gelenberg AJ, Rosenbaum JF, Walzer EA, Baker LA. Subsyndromal symptoms in bipolar disorder: a comparison of standard and low serum levels of lithium. Arch Gen Psychiatry 1992;49:371-6.
5. Carlson GA, Kotin J, Davenport YB, Adland M. Follow-up of 53 bipolar manic-depressive patients. Br J Psychiatry 1974;124: 134-9.
6. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990;47:1106-11.
7. Coryell W, Scheftner W, Keller M, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993;150:720-7.
8. Chakrabarti S, Kulhara P, Verma SK. Extent and determinants of burden among families of patients with affective disorders. Acta Psychiatr Scand 1992;86:247-52.
9. Bauwens F, Tracy A, Pardoen D, Vander Elst M, Mendlewicz J. Social adjustment of remitted bipolar and unipolar out-patients: a comparison with age- and sex-matched controls. Br J Psychiatry 1991;159:239-44.
10. Goodwin FK, Jamison KR. Suicide. In: Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990:227-44.
11. Zis AP, Goodwin FK. Major affective disorder as a recurrent illness: a critical review. Arch Gen Psychiatry 1979;36:835-9.
12. Winokur G, Coryell W, Keller M, Endicott J, Akiskal H. A prospective follow-up of patients with bipolar and primary unipolar affective disorder. Arch Gen Psychiatry 1993;50:457-65.
13. Prien RF. Maintenance treatment of depressive and manic states. In: Georgotas A, Cancro R, eds. Depression and mania. New York: Elsevier, 1988:439-51.
14. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH collaborative study group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096-104.
15. Shapiro DR, Quitkin FM, Fleiss JL. Response to maintenance therapy in bipolar illness: effect of index episode. Arch Gen Psychiatry 1989;46:401-5.
16. Harrow M, Goldberg JF, Grossman LS, Meltzer HY. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990;47:665-71.
17. Maj M, Pirozzi R, Kemali D. Long-term outcome of lithium prophylaxis in bipolar patients [letter]. Arch Gen Psychiatry 1991; 48:772.
18. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489-93.
19. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974;30:229-33.
20. Prien RF, Himmelhoch JM, Kupfer DJ. Treatment of mixed mania. J Affect Disord 1988;15:9-15.
21. Post RM, Rubinow DR, Uhde TW, Roy-Byrne RP, Linnoila M, Rosoff A, Cowdry R. Dysphoric mania: clinical and biological correlates. Arch Gen Psychiatry 1989;46:353-8.
22. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry 1991;148:1237-9.
23. Tohen M, Waternaux CM, Tsuang MT, Hunt AT. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord 1990;19:79-86.
24. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord 1986;10:115-25.
25. Stallone F, Shelley E, Mendlewicz J, Fieve RR. The use of lithium in affective disorders. III: a double blind study of prophylaxis in bipolar disorder. Am J Psychiatry 1973;130:1006-10.
26. O'Connell RA, Mayo JA, Eng LK, Jones JS, Gabel RH. Social support and long-term lithium outcome. Br J Psychiatry 1985;147: 272-5.
27. Miklowitz DJ, Goldstein MJ, Nuechterlein KH, Snyder KS, Mintz J. Family factors and the course of bipolar affective disorder. Arch Gen Psychiatry 1988;45:225-31.
28. Pope HG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991;48:62-8.
29. Lambert PA. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Elsevier, 1984:33-44.
30. Puzynski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders. J Affect Disord 1984;6: 115-21.
31. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985;8:243-50.
32. McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol 1988;8:275-9.
33. Hayes SG. Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 1989;50[suppl 3]:35-9.
34. Fogelson DL, Jacobson S, Sternbach H. A retrospective study of valproate in private psychiatric practice. Ann Clin Psychiatry 1991;3:315-20.
35. Guscott R. Clinical experience with valproic acid in 22 patients with refractory bipolar mood disorder [letter]. Can J Psychiatry 1992;37:590.
36. Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993;13:280-3.
37. Schaff MR, Fawcett J, Zajecka JM. Divalproex sodium in the treatment of refractory mood disorders. J Clin Psychiatry 1993;54: 380-4.
38. Post RM, Leverich GS, Rosoff AS, Altshuler LL. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990;10:318-27.
39. Frankenburg FR, Tohen M, Cohen BM, Lipinski JF. Long-term response to carbamazepine: a retrospective study. J Clin Psychopharmacol 1988;8:130-2.
40. Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mon A, Watanabe S. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl) 1981;73:95-6.
41. Lusznat RM, Murphy DP, Nunn CMH. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988;153:198-204.
42. Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, Small IF. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48: 915-21.
43. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85:114-8.
44. Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. Am J Psychiatry 1994; 151[suppl 12]:1-36.
45. The Expert Consensus Guideline Series. Treatment of bipolar disorder. Steering Committee. American Psychiatric Association. J Clin Psychiatry 1996;57[suppl 12A]:3-88.
46. Hortobagyl GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
47. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B, Adelson MD, Hoskins WJ. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
48. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662-9.
49. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-7.
50. Ferrendelli JA. Relating pharmacology to clinical practice: the pharmacologic basis of rational polypharmacy. Neurology 1995; 45[suppl 2]:S12-S16.
51. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). JAMA 1996;276:1397-403.
52. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, Mela GS, Pilotto A, Plebani M, Davi G. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
53. Nichol MB, Stimmel GL, Lange SC. Factors predicting the use of multiple psychotropic medications. J Clin Psychiatry 1995; 56:60-6.
54. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996;153: 993-1000.
55. Denicoff KD, Blake KD, Smith-Jackson EE, Jacob PA, Leverich G, Post RM. Morbidity in treated bipolar disorder: a one-year prospective study using daily life charts. Depression 1994;2:95-104.
56. Sachs GS. Use of clonazepam for bipolar affective disorder. J Clin Psychiatry 1990;51[suppl]:31-4.
57. Prien RF, Potter WZ. NIMH workshop report on treatment of bipolar disorder. Psychopharmacol Bull 1990;26:409-27.
58. Keck PE, McElroy SL, Stratkowski SM, Balistreri TM, Kizer DL, West SA. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996;57:147-51.
59. Sernyak MJ, Griffin RA, Johnson RM, Pearsall HR, Wexler BE, Woods SW. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am J Psychiatry 1994;151:133-5.
60. Anderson DN. A comparison of in-patient and out-patient prescribing. Br J Psychiatry 1989;154:644-9.
61. Rosholm JU, Hallas J, Gram LF. Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out-patients - a prescription database study. Br J Clin Pharmacol 1994; 37:533-8.
62. Inoue K, Arima S, Tanaka K, Kukui Y, Kato N. A lithium and carbamazepine combination in the treatment of bipolar disorder - a preliminary report. Folia Psychiatr Neurol Jpn 1981;35:465-76.
63. Shukla S, Cook BL, Miller MG. Lithium-carbamazepine versus lithium-neuroleptic prophylaxis in bipolar illness. J Affect Disord 1985;9:219-22.
64. Kishimoto A. The treatment of affective disorder with carbamazepine: prophylactic synergism of lithium and carbamazepine combination. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16:483-93.
65. Boccherta A, Chillotti C, Severino G, Ardau R, Del Zompo M. Carbamazepine augmentation in lithium-refractory bipolar patients: a prospective study on long-term prophylactic effectiveness. J Clin Psychopharmacol 1997;17:92-6.
66. Sachs GS, Rosenbaum JF, Jones L. Adjunctive clonazepam for maintenance treatment of bipolar affective disorder. J Clin Psychopharmacol 1990;10:42-7.
67. Lowe MR, Batchelor DH. Depot neuroleptics and manic depressive psychosis. Int Clin Psychopharmacol 1986;1:53-62.
68. Peselow ED, Fieve RR, Difiglia C, Sanfilipo MP. Lithium prophylaxis of bipolar illness: the value of combination treatment. Br J Psychiatry 1994;164:208-14.
69. Calabrese JR, Delucchi GA. Phenomenology of rapid cycling manic depression and its treatment with valproate. J Clin Psychiatry 1989;50[suppl 3]:30-4.
70. Keck PE, McElroy SL, Vuckovic A, Friedman LM. Combined valproate and carbamazepine treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:319-22.
71. Del Zompo M, Burrai C, Piccardi MP, Marelli A, Corsini GU. Prophylactic efficacy of carbamazepine in lithium-resistant affective disorders. In: Corsini GU, ed. Current trends in lithium and rubidium therapy. Lancaster, England: MTP Press, 1984:325-30.
72. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. Arch Gen Psychiatry 1990;47:435-40.
73. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993;8:119-22.
74. Banov MD, Zarate CA, Tohen M, Scialabba D, Wines JD, Kolbrener M, Kim JW, Cole JO. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994;55:295-300.
75. Suppes T, Phillips KA, Judd CR. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry 1994;36:338-40.
76. Joyce PR. Carbamazepine in rapid cycling bipolar affective disorder. Int Clin Psychopharmacol 1988;3:123-9.
77. Di Costanzo E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. Acta Psychiatr Scand 1991;83:456-9.
78. Aronson TA, Shukla S, Hirschowitz J. Clonazepam treatment of five lithium-refractory patients with bipolar disorder. Am J Psychiany 1989;146:77-80.
79. Quitkin FM, Kane J, Rifkin A, Ramos-Lorenzi JR, Nayak DV. Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. A double-blind study. Arch Gen Psychiatry 1981;38:902-7.
80. Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams JJ. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull 1995;31: 265-72.
81. Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AHW, Hopwood SE. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986;148:723-5.
82. Suppes T, Calabrese JR, Mitchell PB, Pazzaglia PJ, Potter WZ, Zarin DA. Algorithms for the treatment of bipolar, manic-depressive illness. Psychopharmacol Bull 1995;31:469-74.
83. Prien RF, Rush AJ. National Institute of Mental Health workshop report on the treatment of bipolar disorder. Biol Psychiatry 1996;40:215-20.
84. Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A, Keller MB. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997;58: 95-9.
85. Berry KJ, Mielke PW Jr. R by c chi-square analyses with small expected cell frequencies. Educ Psychol Meas 1986;46:169-73.
86. Sharma V, Persad E, Mazmanian D, Karunaratne K. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry 1993;38:137-9.
87. Sharma V, Persad E. Augmentation of valproate with lithium in a case of rapid cycling bipolar disorder. Can J Psychiatry 1992; 37:584-5.
88. Mitchell P, Withers K, Jacobs G, Hickie I. Combining lithium and sodium valproate for bipolar disorder. Aust N Z J Psychiatry 1994;28:141-3.
89. Fenn HH, Robinson D, Luby V, Dangel C, Buxton E, Beattie M, Kraemer H, Yesavage JA. Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. Am J Psychiatry 1996;153:711-3.
90. Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Pract Psychiatry Behav Health 1995;1:92-8.
91. Pope HG, McElroy SC, Satlin A, Hudson JI, Keck PE, Kalish SR. Head injury, bipolar disorder, and response to valproate. Compr Psychiatry 1988;29:34-8.
92. Granneman GR, Schneck DW, Cavanaugh JH, Witt GF. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J Clin Psychiatry 1996;57:204-6.
93. Hardman JG, Limbird LE. Goodman and Oilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996.
94. Schatzberg AF, Nemeroff CB. The American Psychiatric Press textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995.
95. Lenox RH, McNamara RK, Watterson JM, Watson DG. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 1996;57[suppl 13]:23-31.
96. Bowden CL. Predictors of response to divalproex and lithium. J Clin Psychiatry 1995;56[suppl 3]:25-30.
97. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271: 918-24.
98. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, Dilsaver SC, Davis JM. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54:37-42.
99. Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995;56: 118-21.